Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00339066 |
|
Recruitment Status :
Completed
First Posted : June 20, 2006
Last Update Posted : August 9, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Depression | Drug: Sertraline | Not Applicable |
Depression in older adults is a major public health problem and it often goes underdiagnosed and undertreated. A significant number of people with LLD, especially those with cerebrovascular risk factors, have subcortical grey matter and frontal deep white matter brain lesions. Some studies suggest that these lesions, or hyperintensities, may be associated with poor acute and long-term depression treatment response. Similarly, studies have shown that people with LLD frequently have functional deficits in the frontal lobe portion of their brains. This dysfunction has been shown to be associated with poor acute treatment response with a tricyclic antidepressant drug, as well as with a greater risk for depression relapse. The applicability of these findings to other classes of antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), however, remains unknown. Additionally, more information is needed about the interaction between frontal brain lesions and executive function deficits in LLD. This study will determine the relationship between brain lesion severity, treatment response, and frontal lobe function in people with late-life depression who are being treated with the SSRI sertraline.
Participants in this open label study will first undergo neuropsychological testing to determine eligibility. All eligible participants will be treated with sertraline for 12 weeks. Dosages will begin at 25 mg per day, and will be increased to 50 mg per day after 4 days. Any other dosage modifications will depend on the participant's individual response to the medication. All participants will have an MRI scan at some point during the study. Assessments of symptoms and treatment response will occur at the study site biweekly until Week 8, and then again at Week 12.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 131 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Treatment Outcomes of Vascular Depression |
| Study Start Date : | August 2001 |
| Actual Primary Completion Date : | March 2006 |
| Actual Study Completion Date : | March 2006 |
- Measured at Week 12: Montgomery-Asberg Depression Scale (MADRS)
- Measured at Week 12: Hamilton Depression Rating Scale (Ham-D)
- Clinical Global Impression (CGI)
- Quality of Life Assessment
- Disability Assessment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- DSM-IV of major depressive disorder (MDD)
- Score of greater than 20 on the MADRS (score of greater than 17 for atypical depression)
- Score of greater than 20 on the Mini Mental State Examination (MMSE)
Exclusion Criteria:
- Any condition that may make having an MRI medically inadvisable
- Any severe or unstable medical conditions
- Any known primary neurological disorders, including history of stroke
- Any other simultaneous Axis I disorder
- History of substance or alcohol abuse disorder within 6 months prior to study entry
- Currently at risk for suicide
- History of failed prior adequate trials of two antidepressants for the current depressive episode
- History of failed prior adequate trial of sertraline
- Current use of any other psychoactive medications (medication washout will be required)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00339066
| United States, Missouri | |
| Washington University in St. Louis | |
| St. Louis, Missouri, United States, 63130 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27706 | |
| Principal Investigator: | P. Murali Doraiswamy, MD | Duke University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Duke University |
| ClinicalTrials.gov Identifier: | NCT00339066 History of Changes |
| Other Study ID Numbers: |
2524 R01MH062158 ( U.S. NIH Grant/Contract ) DATR A4-GPX |
| First Posted: | June 20, 2006 Key Record Dates |
| Last Update Posted: | August 9, 2013 |
| Last Verified: | February 2008 |
Keywords provided by Duke University:
|
Late-Life Depression |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders Sertraline Antidepressive Agents Psychotropic Drugs |
Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs |